Recent in vivo data revealed that telomestatin potently eradicates glioma stem cells (GSC) through telomere disruption and c-Myb inhibition, suggesting a novel GSC-directed therapeutic strategy for glioblastoma multiforme (GBM) [162]. This evidence concerns the gene MYB and glioblastoma.